Last reviewed · How we verify
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT)
The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.
Details
| Lead sponsor | University of Birmingham |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 284 |
| Start date | Mon Sep 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Nov 30 2031 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma
Interventions
- Epcoritamab
- Lenalidomide
- Rituximab
- Obinutuzumab
- Bendamustine
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
- Investigation agent 2
Countries
United Kingdom